J
Joon Oh Park
Researcher at Harvard University
Publications - 5
Citations - 4430
Joon Oh Park is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Receptor tyrosine kinase. The author has an hindex of 3, co-authored 5 publications receiving 4162 citations. Previous affiliations of Joon Oh Park include Samsung Medical Center.
Papers
More filters
Journal ArticleDOI
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman,Kreshnik Zejnullahu,Tetsuya Mitsudomi,Youngchul Song,Courtney Hyland,Joon Oh Park,Neal I. Lindeman,Christopher-Michael Gale,Xiaojun Zhao,James J. Christensen,Takayuki Kosaka,Alison J. Holmes,Andrew M. Rogers,Federico Cappuzzo,Tony Mok,Charles Lee,Bruce E. Johnson,Lewis C. Cantley,Pasi A. Jänne +18 more
TL;DR: It is proposed that MET amplification may promote drug resistance in other ERBB-driven cancers as well after it was found that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)–dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.
Journal ArticleDOI
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
Jussi Koivunen,Jhingook Kim,Jong Kyun Lee,Andrew M. Rogers,Joon Oh Park,Xiaojun Zhao,Katsuhiko Naoki,Isamu Okamoto,Kazuhiko Nakagawa,Beow Y. Yeap,Matthew Meyerson,Kwok-Kin Wong,William G. Richards,David J. Sugarbaker,Bruce E. Johnson,Pasi A. Jänne +15 more
TL;DR: Clinical and molecular characteristics of NSCLC, which harbour LKB1 mutations, are provided, including those with adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma histologies.
Journal ArticleDOI
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression
Toru Mukohara,Hiroyuki Shimada,Naomi Ogasawara,Ryoko Wanikawa,Manami Shimomura,Tetsuya Nakatsura,Genichiro Ishii,Joon Oh Park,Joon Oh Park,Pasi A. Jänne,Nagahiro Saijo,Hironobu Minami +11 more
TL;DR: Investigation of the effects of NVP-AEW541 in breast cancer cell lines suggests that inhibiting IGF-1R may be an effective therapeutic strategy for breast cancers that co-express IGF- 1R and IRS-1 at high levels.
Journal ArticleDOI
C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines.
Joon Oh Park,Feng Zhao,Kreshnik Zejnullahu,Emmanuel Normant,Jeffrey A. Engelman,Bruce E. Johnson,Pasi A. Jänne +6 more
TL;DR: This randomised, placebo-controlled, multicentre 3-arm phase III study compared the efficacy of two doses of bevacizumab in combination with CG versus CG plus placebo and met its primary endpoint in PFS.
Journal ArticleDOI
D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors
Jeffrey A. Engelman,Kreshnik Zejnullahu,Tetsuya Mitsudomi,Courtney Hyland,Joon Oh Park,Neal I. Lindeman,Christopher-Michael Gale,Xiaojun Zhao,James D. Christensen,Rogers M. Rogers,Federico Cappuzzo,Tony Mok,Charles Lee,Johnson E. Bruce,Lewis C. Cantley,Pasi A. Jänne +15 more